Rev. OFIL 2018, 28;1:79-80
Fecha de recepción: 03/07/2017 – Fecha de aceptación: 13/09/2017
Meroño Saura MA, Rodríguez Martínez T, Ventura López M, Gómez Gil A
Hospital General Universitario Morales Meseguer. Murcia (España)
____
SUMMARY
Primary immune thrombocytopenia is an autoimmune disorder produced by two mechanisms; premature platelet destruction mediated by autoantibodies and an impaired platelet production. Signs and symptoms are variable, highlighting mucocutaneous haemorrhages. Treatment aims to increase platelet counts to figures that can prevent bleeding.
We describe the case of a patient with PTI refractory to standard therapies and who need combined treatment with romiplostim and rituximab, an off-label combination. There is a sustained increase in platelet count and a mild adverse reaction profile. Further safety and efficacy studies of this combination are necessary to consider it a treatment option in the PTI.
Key Words: Rituximab, romiplostim, idiopathic thrombocytopenic purpura.
____
Correspondencia:
Mª Antonia Meroño Saura
Hospital Morales Meseguer
(Servicio de Farmacia)
Avda. Marqués de los Velez, s/n
30008 Murcia
Correo electrónico: toxims_15@hotmail.com
____
Download full article – PDF: Caso Clínico: Uso combinado de rituximab y romiplostim en púrpura trombocitopénica idiopática